IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000238
PRESS-ONLY PREVIEW OF THE ARTICLE: www.plos.org/press/plme-07-02-huang.pdf
University of California Irvine
Division of Infectious Diseases
101 The City Drive South
City Tower, Suite 400,
Orange, CA 92868-3217
United States of America
Rate of T cell count drop not found helpful in deciding when to start HIV treatment
Published this week in open access journal PLoS Medicine, Marcel Wolbers (Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit) and colleagues find that the rate of CD4 T cell decline is not useful in deciding when to start HIV treatment.
Wolbers and colleagues analyzed data from several thousand cohort study participants with HIV (the CASCADE collaboration) and found that the CD4 cell slope does not improve the prediction of clinical outcome in patients with a CD4 cell count above 350 cells/μl. The authors state "the findings of this study strongly suggest that knowledge of the current CD4 cell count and an assessment of other established risk factors for progression to AIDS are sufficient when deciding whether to initiate cART in symptom-free HIV-positive patients."
Citation: Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, et al. (2010) Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral TherapyThe CASCADE Collaboration: A Collaboration of 23 Cohort Studies. PLoS Med 7(2): e1000239. doi:10.1371/journal.pmed.1000239<
|Contact: Andrew Hyde|
Public Library of Science